journal
https://read.qxmd.com/read/38603956/cesarean-hysterectomy-for-placenta-accreta-spectrum-surgeon-specialty-specific-assessment
#1
JOURNAL ARTICLE
Koji Matsuo, Yongmei Huang, Shinya Matsuzaki, Andrew Vallejo, Joseph G Ouzounian, Lynda D Roman, Fady Khoury-Collado, Alexander M Friedman, Jason D Wright
OBJECTIVE: To assess (i) clinical and pregnancy characteristics, (ii) patterns of surgical procedures, and (iii) surgical morbidity associated with cesarean hysterectomy for placenta accreta spectrum based on the specialty of the attending surgeon. METHODS: The Premier Healthcare Database was queried retrospectively to study patients with placenta accreta spectrum who underwent cesarean delivery and concurrent hysterectomy from 2016 to 2020. Surgical morbidity was assessed with propensity score inverse probability of treatment weighting based on surgeon specialty for hysterectomy: general obstetrician-gynecologists, maternal-fetal medicine specialists, and gynecologic oncologists...
April 10, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38603955/adoptive-t-cell-therapy-for-ovarian-cancer
#2
REVIEW
Sarah B Gitto, Chibuike J N Ihewulezi, Daniel J Powell
Although ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated with better patient outcome. Thus, harnessing the immune system through passive administration of T cells, a process called adoptive cell therapy (ACT), is a promising therapeutic option for the treatment of ovarian cancer...
April 10, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38603954/has-time-to-chemotherapy-from-primary-debulking-surgery-in-advanced-ovarian-cancer-an-impact-on-survival-a-population-based-nationwide-swegcg-study
#3
JOURNAL ARTICLE
Pernilla Dahm-Kähler, Angelique Flöter Rådestad, Erik Holmberg, Christer Borgfeldt, Maria Bjurberg, Camilla Sköld, Kristina Hellman, Preben Kjølhede, Karin Stålberg, Elisabeth Åvall-Lundqvist
OBJECTIVE: The aim of the study was to investigate if time to start chemotherapy (TTC) after primary debulking surgery (PDS) impacted relative survival (RS) in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer (EOC). METHODS: Nationwide population-based study of women with EOC FIGO stages IIIC-IV, registered 2008-2018 in the Swedish Quality Register for Gynecologic Cancer, treated with PDS and chemotherapy. TTC was categorized into; ≤21 days, 22-28 days, 29-35 days, 36-42 days and > 42 days...
April 10, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38603953/phase-ii-trial-of-pembrolizumab-and-epacadostat-in-recurrent-clear-cell-carcinoma-of-the-ovary-an-nrg-oncology-study-gy016
#4
JOURNAL ARTICLE
Lilian T Gien, Danielle M Enserro, Matthew S Block, Steven Waggoner, Linda R Duska, Andrea E Wahner-Hendrickson, Premal H Thaker, Floor Backes, Michael Kidd, Carolyn Y Muller, Paul A DiSilvestro, Allan Covens, David M Gershenson, Kathleen N Moore, Carol Aghajanian, Robert L Coleman
INTRODUCTION: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC. METHODS: This single arm, two-stage, phase 2 trial included those with measurable disease and 1-3 prior regimens. Patients received intravenous pembrolizumab 200 mg every 3 weeks and oral epacadostat 100 mg twice a day. Primary endpoint was overall response rate (ORR), secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS)...
April 10, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38599112/predictors-of-germline-genetic-testing-referral-and-completion-in-ovarian-cancer-patients-at-a-comprehensive-cancer-center
#5
JOURNAL ARTICLE
Katherine W Saylor, Elizabeth Q Fernandes, Michael Adams, Sarah Paraghamian, David I Shalowitz
OBJECTIVES: To identify predictors of referral and completion of germline genetic testing among newly diagnosed ovarian cancer patients, with a focus on geographic social deprivation, oncologist-level practices, and time between diagnosis and completion of testing. METHODS: Clinical and sociodemographic data were abstracted from medical records of patients newly diagnosed with ovarian cancer between 2014 and 2019 in the University of North Carolina Health System...
April 8, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38593674/disease-progression-survival-and-molecular-disparities-in-black-and-white-patients-with-endometrioid-endometrial-carcinoma-in-real-world-registries-and-gog-nrg-oncology-randomized-phase-iii-clinical-trials
#6
JOURNAL ARTICLE
Zachary A Kopelman, Chunqiao Tian, Jordyn Tumas, Neil T Phippen, Christopher M Tarney, Erica R Hope, Stuart S Winkler, Suzanne Jokajtys, Calen W Kucera, John K Chan, Michael T Richardson, Daniel S Kapp, Chad A Hamilton, Charles A Leath, Nathaniel L Jones, Rodney P Rocconi, John H Farley, Angeles Alvarez Secord, Casey M Cosgrove, Matthew A Powell, Ann Klopp, Joan L Walker, Gini F Fleming, Nicholas W Bateman, Thomas P Conrads, G Larry Maxwell, Kathleen M Darcy
OBJECTIVE: Investigate racial disparities in outcomes and molecular features in Black and White patients with endometrioid endometrial carcinoma (EEC). METHODS: Black and White patients diagnosed with EEC who underwent hysterectomy ± adjuvant treatment in SEER, National Cancer Database (NCDB), the Genomics Evidence Neoplasia Information Exchange (GENIE) project (v.13.0), and eight NCI-sponsored randomized phase III clinical trials (RCTs) were studied. Hazard ratio (HR) and 95% confidence interval (CI) were estimated for cancer-related death (CRD), non-cancer death (NCD), and all-cause death...
April 8, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38582027/high-throughput-screening-identifies-dasatinib-as-synergistic-with-trametinib-in-low-grade-serous-ovarian-carcinoma
#7
JOURNAL ARTICLE
Robert L Hollis, Richard Elliott, John C Dawson, Narthana Ilenkovan, Rosie M Matthews, Lorna J Stillie, Ailsa J Oswald, Hannah Kim, Marta Llaurado Fernandez, Michael Churchman, Joanna M Porter, Patricia Roxburgh, Asier Unciti-Broceta, David M Gershenson, C Simon Herrington, Mark S Carey, Neil O Carragher, Charlie Gourley
BACKGROUND: Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening in clinically-informative cell-based models represents an attractive strategy for identifying candidate treatment options for prioritisation in clinical studies. METHODS: We performed a high throughput drug screen of 1610 agents across a panel of 6 LGSOC cell lines (3 RAS/RAF-mutant, 3 RAS/RAF-wildtype) to identify novel candidate therapeutic approaches...
April 5, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38569327/reducing-radicality-in-fertility-sparing-surgery-is-associated-with-improved-in-vitro-fertilization-outcome-in-early-stage-cervical-cancer-a-national-retrospective-study
#8
JOURNAL ARTICLE
Dóra Vesztergom, Gyöngyvér Téglás, Kiarash Bahrehmand, Attila Török, Levente Balla, Vince Forgács, János Konc, Zoltán Tándor, Ákos Várnagy, Péter Boga, János Zádori, Miklós Sipos, Zoltán Mánfai, Zoltán Novák
OBJECTIVE: Fertility-sparing surgery (FSS) aims to achieve oncological outcomes that are non-inferior to radical treatment while preserving fertility and optimizing reproductive results. This study assesses in vitro fertilization (IVF) outcomes in early-stage cervical cancer survivors following FSS, comparing radical and non-radical approaches. METHODS: This retrospective analysis used data from Hungary's National Health Insurance Fund (2004-2022) on patients who underwent IVF treatment following FSS for early-stage cervical cancer at ten Hungarian fertility clinics...
April 1, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38555766/tp53-mutations-and-the-association-with-platinum-resistance-in-high-grade-serous-ovarian-carcinoma
#9
JOURNAL ARTICLE
Lauren Montemorano, Zoey B Shultz, Alma Farooque, Meredith Hyun, Richard J Chappell, Ellen M Hartenbach, Jessica D Lang
OBJECTIVES: Alterations in the tumor suppressor TP53 gene are the most common mutations in high grade serous ovarian carcinoma. The impact of TP53 mutations on clinical outcomes and platinum resistance is controversial. We sought to evaluate the genomic profile of high grade serous ovarian carcinoma and explore the association of TP53 mutations with platinum resistance. METHODS: Next generation sequencing data was obtained from our institutional database for patients with high grade serous ovarian carcinoma undergoing primary treatment...
March 30, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38555710/high-dose-ascorbate-exerts-anti-tumor-activities-and-improves-inhibitory-effect-of-carboplatin-through-the-pro-oxidant-function-pathway-in-uterine-serous-carcinoma-cell-lines
#10
JOURNAL ARTICLE
Xiaochang Shen, Jiandong Wang, Boer Deng, Shuning Chen, Catherine John, Ziyi Zhao, Nikita Sinha, Jennifer Haag, Wenchuan Sun, Weimin Kong, Ivan Spasojevic, Ines Batinic-Haberle, Angeles Alvarez Secord, Chunxiao Zhou, Victoria L Bae-Jump
OBJECTIVE: Uterine serous carcinoma is a highly aggressive non-endometrioid subtype of endometrial cancer with poor survival rates overall, creating a strong need for new therapeutic strategies to improve outcomes. High-dose ascorbate (vitamin C) has been shown to inhibit cell proliferation and tumor growth in multiple preclinical models and has shown promising anti-tumor activity in combination with chemotherapy, with a favorable safety profile. We aimed to study the anti-tumor effects of ascorbate and its synergistic effect with carboplatin on uterine serous carcinoma cells...
March 30, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38555709/delayed-publication-of-clinical-trials-in-gynecologic-oncology
#11
JOURNAL ARTICLE
Julia R Salinaro, Emma C Rossi, Katherine N Penvose, Yingao Zhang, Alice J Darling
OBJECTIVES: Delays in clinical trial publication can hinder timely implementation of evidence-based practices. We sought to determine publication rates and time to publication for clinical trials addressing gynecologic malignancies. METHODS: All clinical trials addressing gynecologic cancers in the ClinicalTrials.gov registry with a primary completion date between 1/1/2018 and 1/1/2020 were identified. The primary outcome was publication rate. All included studies had been completed for at least 3 years...
March 30, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38554626/comparing-survival-of-older-ovarian-cancer-patients-treated-with-neoadjuvant-chemotherapy-versus-primary-cytoreductive-surgery-reducing-bias-through-machine-learning
#12
JOURNAL ARTICLE
Yongmei Huang, J Alejandro Rauh-Hain, Thomas H McCoy, June Y Hou, Grace Hillyer, Jennifer S Ferris, Dawn Hershman, Jason D Wright, Alexander Melamed
OBJECTIVE: To develop and evaluate a multidimensional comorbidity index (MCI) that identifies ovarian cancer patients at risk of early mortality more accurately than the Charlson Comorbidity Index (CCI) for use in health services research. METHODS: We utilized SEER-Medicare data to identify patients with stage IIIC and IV ovarian cancer, diagnosed in 2010-2015. We employed partial least squares regression, a supervised machine learning algorithm, to develop the MCI by extracting latent factors that optimally captured the variation in health insurance claims made in the year preceding cancer diagnosis, and 1-year mortality...
March 29, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38554625/the-association-of-histopathologic-features-after-neoadjuvant-chemo-immunotherapy-with-clinical-outcome-sub-analyses-from-the-randomized-double-blinded-placebo-controlled-phase-iii-imagyn050-gog3015-engot-ov39-study
#13
JOURNAL ARTICLE
Paulette Mhawech-Fauceglia, Denis McCarthy, Akiko Tonooka, Giovanni Scambia, Yolanda Garcia, Pavel Dundr, Anne M Mills, Kathleen Moore, Sakiko Sanada, Leslie Bradford, Giulia Carlo Stella, Michael Bookman, Sudarshan K Sharma, Frederic Selle, Luciana Molinero, Yvette He, Victor Khor, Charles Landen, Yvonne G Lin
OBJECTIVE: Histopathologic characteristics after neoadjuvant chemotherapy (NACT) may correlate with outcome. This study evaluates histopathologic features after immunotherapy and NACT/bevacizumab, and associated clinical outcomes. METHODS: Evaluable tissue from IMagyn050/GOG3015/ENGOT-ov39 patients from prespecified anatomic sites from interval cytoreductive surgery (ICS) after NACT/bevacizumab plus atezolizumab/placebo underwent central histopathologic scoring and analyzed with clinical outcomes...
March 29, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38554624/healthcare-utilization-in-women-diagnosed-with-endometrial-cancer-a-survey-based-study
#14
JOURNAL ARTICLE
Nerlyne Desravines, Dana Hazimeh, Michael R Desjardins, Stephanie L Wethington
OBJECTIVE: Despite similar incidence, non-Hispanic Black women are twice as likely to die of endometrial cancer as non-Hispanic White women. The social determinants of health may contribute to this disparity. We studied barriers to care and social needs of endometrial cancer patients. METHODS: In a cohort of patients with endometrial cancer from the All of Us study, participants self-reported demographics and completed validated surveys (access to medical care, transportation, caregiving, finances, medication, general care, specialty care, housing insecurity)...
March 29, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38554478/system-level-recommendations-for-improved-wellness-for-gynecologic-oncologists-a-society-of-gynecologic-oncology-review
#15
REVIEW
M Y Williams-Brown, R M Summey, A Newtson, W Burke, T Turner, P Sabu, B A Davidson, G Glaser
Burnout and its negative sequelae are a persistent problem in gynecologic oncology, threatening the health of our physician workforce. Individual-level interventions such as stress management training, physical activity, and sleep hygiene only partially address this widespread, systemic crisis rooted in the extended work hours and stressful situations associated with gynecologic oncology practice. There is an urgent need for systematic, institution-level changes to allow gynecologic oncologists to continue the crucial work of caring for people with gynecologic cancer...
March 29, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38554477/cost-effectiveness-of-chemotherapy-and-dostarlimab-for-advanced-or-recurrent-endometrial-cancer
#16
JOURNAL ARTICLE
Courtney J Riedinger, David A Barrington, Christa I Nagel, Wafa K Khadraoui, Paulina J Haight, Crystal Tubbs, Floor J Backes, David E Cohn, David M O'Malley, Larry J Copeland, Laura M Chambers
OBJECTIVE: The combination of dostarlimab with carboplatin and paclitaxel has demonstrated improved progression-free survival (PFS) and overall survival (OS) in primary advanced and recurrent endometrial cancer (EC). However, prior studies have not found immunotherapy to be cost-effective, or cost-effective only in specific subgroups, of recurrent endometrial cancer. This study aimed to determine the cost-effectiveness of combination therapy compared to chemotherapy alone. METHOD: A partitioned survival model was developed to compare the cost and effectiveness of dostarlimab in combination with chemotherapy compared to chemotherapy alone in primary advanced or recurrent endometrial cancer...
March 29, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38520881/treatment-outcomes-according-to-various-progestin-treatment-strategies-in-patients-with-atypical-hyperplasia-endometrial-intraepithelial-neoplasia-multicenter-retrospective-study-kgog2033
#17
JOURNAL ARTICLE
Nam Kyeong Kim, Chel Hun Choi, Seok Ju Seong, Jong-Min Lee, Banghyun Lee, Kidong Kim
OBJECTIVE: To investigate pathologic complete response (pCR) and recurrence outcomes using various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN). METHODS: Medical records of patients diagnosed with AH/EIN and undergoing follow-up endometrial biopsy after progestin treatment between 2011 and 2020 were retrospectively reviewed. Clinical factors and treatment outcomes were analyzed according to initial progestin treatment (oral progestin [OP], levonorgestrel-releasing intrauterine device [LNG-IUD], and combination), OP dose, and maintenance treatment using Pearson's χ2 , Fisher's exact test, and Kaplan-Meier analysis...
March 22, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38518529/alpelisib-for-pik3ca-mutated-advanced-gynecological-cancers-first-clues-of-clinical-activity
#18
JOURNAL ARTICLE
Anna Passarelli, Vittoria Carbone, Sandro Pignata, Roberta Mazzeo, Domenica Lorusso, Giovanni Scambia, Stefania Canova, Teresa Di Palma, Giulia Tasca, Mara Mantiero, Emanuele Naglieri, Claudia Andreetta, Martina Rauso, Anna Elisabetta Brunetti, Letizia Laera, Chiara Abeni, Giuseppa Scandurra, Anna Rita Gambaro, Alessia Pastore, Carmelo Bengala, Marco Gunnellini, Alberto Farolfi, Maurizio Spinello, Michele Bartoletti
OBJECTIVE: Recurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options are urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential treatment target. Alpelisib is an α-specific PI3K inhibitor approved in PIK3CA-mutated advanced breast cancer. We report outcomes from a large series of patients with PIK3CA-mutated gynecological cancers prospectively treated with alpelisib within a controlled program...
March 21, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38518528/dedicated-financial-hardship-screening-adds-value-to-routine-distress-screening-among-gynecologic-cancer-patients
#19
JOURNAL ARTICLE
Margaret I Liang, Jhalak D Dholakia, Grace M Lee, Lingling Wang, Tavonna D Kako, Isabella Blair, Courtney P Williams, Rebecca C Arend, Warner K Huh, Gabrielle B Rocque, Maria Pisu
OBJECTIVES: To evaluate existing distress screening to identify patients with financial hardship (FH) compared to dedicated FH screening and assess patient attitudes toward FH screening. METHODS: We screened gynecologic cancer patients starting a new line of therapy. Existing screening included: (1) Moderate/severe distress defined as Distress Thermometer score ≥ 4, (2) practical concerns identified from Problem Checklist, and (3) a single question assessing trouble paying for medications...
March 21, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38514301/response-to-the-letter-to-the-editor
#20
LETTER
Dongjo Ban, Stephen N Housley, Lilya V Matyunina, L DeEtte McDonald, Victoria L Bae-Jump, Benedict B Benigno, Jeffrey Skolnick, John F McDonald
No abstract text is available yet for this article.
March 20, 2024: Gynecologic Oncology
journal
journal
23122
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.